Location & Type arrow_drop_up Concepts arrow_drop_down Orgs arrow_drop_down
#1
Meng Ji
Meng Ji
The University of Sydney, Sydney, Aust Capital Terr, Australia
Known for star star star star star
Indolent Lymphoma | Refractory Diffuse | Chinese Relapsed | Bgb-3111 Combination
#2
Richard Klasa
Richard Klasa
Known for star star star star star
Lymphoid Malignancies | Sb1518 Advanced | Lymphoma Phase | Small Lymphocytic

#3
Veronica Bernard
Veronica Bernard
b Department of Pathology , Reference Centre for Lymph Node Pathology and Hematopathology, University Hospital of Schleswig-Holstein , Luebeck , Germany.
Known for star star star star star_border
Glasgow Prognostic | Malt Lymphoma | Essential Thrombocythemia | Polycythemia Vera
#4
K. E. Flood‐Knapik
K. E. Flood‐Knapik
Known for star star star star star_border
Indolent Lymphoma | Prospective Trials | Biological Behaviour | Marginal Zone
#5
Martin H. Robinson
Martin H. Robinson
Department of Histopathology, Soft Tissue Sarcoma Unit, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
Known for star star star star star_border
Soft Tissue Sarcoma | Local Recurrence | Epoetin Alfa | Virtual Simulation
#6
Liliana Franca Devizzi
Liliana Franca Devizzi
d Division of Hematology , National Cancer Institute , Milan , Italy.
Known for star star star star star_border
Advisory Committees | Heavily Pretreated | Entitys Board | Malt Lymphoma
#7
Francesco Caracciolo
Francesco Caracciolo
Institute of Haematology, University of Pisa. Santa Chiara Hospital, Pisa, Italy
Known for star star star star star_border
Bone Marrow | Minimal Residual | Peripheral Blood | Chronic Myeloid Leukemia
#8
Sadao Aoki
Sadao Aoki
From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal ...
Known for star star star star star_border
Tafro Syndrome | Malignant Lymphoma | Prognostic Factor | Hematological Malignancies
#9
Stacey Kalambakas
Stacey Kalambakas
Clinical Research Science, Celgene Corporation, Summit, United States
Known for star star star star star_border
Advisory Committees | Entitys Board | ≥ 70 | Phase Iii
#10
Giulia Cervetti
Giulia Cervetti
Hematology Division, Department of Oncology, Transplants and Advanced Technologies, University of Pisa, Pisa, Italy. m.petrini@med.unipi.it
Known for star star star star star_border
Chronic Myeloid Leukemia | Splenic Marginal Zone Lymphoma | Dexrazoxane Supplementation | Minimal Residual
#11
Kurt S. Bantilan
Kurt S. Bantilan
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;
Known for star star star star star_border
Advisory Committees | Speakers Bureau | Entitys Board | Interim Pet
#12
Chengqing Wu
Chengqing Wu
Statistics, Celgene International, Boudry, Switzerland
Known for star star star star star_border
Advisory Committees | Entitys Board | ≥ 70 | Phase Iii
#13
Jennifer M. Fiore
Jennifer M. Fiore
Center for Lymphoma and Myeloma, Division of Hematology/Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York
Known for star star star star star_border
131 Tositumomab | Subsequent Therapy | Follicular Lymphoma | B-Cell Malignancies
#14
Lena Mathews
Lena Mathews
Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine,, Weill Medical College of Cornell University and New York Presbyterian ...
Known for star star star star star_border
Marginal Zone Lymphoma | Top-M Chemotherapy | Chop Regimen | Disseminated Mzl
#15
Sedat Demirdas
Sedat Demirdas
Department of Hematology, University Hospital Essen, West German Cancer Center, University of Duisburg-Essen, Essen, Germany
Known for star star star star star_border
Indolent B-Cell Lymphomas | Preceding Diagnosis | Histologic Transformation | Follicular Lymphoma
#16
Paola Agostini
Paola Agostini
From the Dipartimento di Scienze Biomediche e Terapie AvanzateSezione di Ematologia, and Dipartimento di Medicina Sperimentale e Diagnostica, Sezione di Microbiologia, ...
Known for star star star star star_border
Normal Karyotype | Situ Hybridization | 13q14 Deletion | 5q- Syndrome
#17
Isabelle Moullet
Isabelle Moullet
UPRES-JE ‘Pathologie des Cellules Lymphoides’, Université Claude Bernard, Pierre-Bénite, France Service d’Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, ...
Known for star star star star star_border
Soluble Receptors | Platelet Recovery | Chemotherapy-Induced Myelosuppression | Autologous Peripheral Blood Progenitor

 

Recently Asked Questions

View all FAQs

Asthmatic Bronchitis Asthmatic bronchitis is a type of bronchitis, which is an inflammation of the bronchi (the airways that connect the trachea to the lungs). It is...

 

Enuresis Enuresis, also known as bedwetting, is the involuntary leakage of urine. It is a common problem in young children, but can persist into adolescence and...

 

Macroglobulinemia Macroglobulinemia is a condition in which there are too many monoclonal immunoglobulins, or antibodies, in the blood. These immunoglobulins are produced by...

 

Anxiety Headache Anxiety headaches are a type of tension headache. They're usually mild to moderate in intensity. However, they can cause significant distress and disrupt...

 

Spinal Cord Tumor A spinal cord tumor is a mass or growth that develops within the spinal cord or the tissues surrounding it. These tumors can be either benign (noncancerous)...

 

A Phase 2 Study To Assess The Safety, Tolerability, And Activity Of Bgb-3111 In...

[ CLINICAL_TRIAL ] ... Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL)).. This is a multicenter open-label phase 2 study to evaluate efficacy, safety and ...
Known for star star star star star
Indolent Lymphoma | Refractory Diffuse | Bgb-3111 Chinese | Safety Tolerability

A Phase 2 Safety And Efficacy Study Of Sb1518 For The Treatment Of Advanced...

[ CLINICAL_TRIAL ] ... and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).. This is a Phase 2 study to assess the efficacy of SB1518 in ...
Known for star star star star star
Advanced Lymphoid | Lymphoma Phase | Safety Sb1518 | Malignancies Hodgkin

A Phase Ii Multicenter Non-Randomized Study To Assess Safety, Toxicity And...

[ CLINICAL_TRIAL ] ... sensitive indolent non-follicular and mantle cell non-Hodgkin's lymphoma. Despite of the availability of treatment for this disease, this study is justified because no known therapies are
Known for star star star star star
Refractory Indolent | Hodgkin Lymphoma | Bortezomib Rituximab | Assess Safety

Safety And Activity Of Rituximab(Hlx01) In Combination With Pegylated Interferon...

[ CLINICAL_TRIAL ] ... advanced indolent B-cell lymphoma. Detailed Description Indolent B-cell lymphomas (iBCL), including follicular lymphoma (FL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL, ...
Known for star star star star star_half
Pegylated Interferon | Advanced Indolent | Newly Diagnosed | Activity Rituximabhlx01

Phase Ii Study Of Gemcitabine In Patients With Advanced Stage Marginal Zone...

[ CLINICAL_TRIAL ] ... the indolent lymphoma, is believed to be incurable with chemotherapy. Thus the investigators need a novel agent for marginal zone lymphoma. Gemcitabine has been tried as one of salvage ...
Known for star star star star star_half
Marginal Zone | Lymphoma Gemcitabine | Advanced Stage | Chemotherapy Agent

A Phase 3, Double-Blind, Randomized Study To Compare The Efficacy And Safety Of...

[ CLINICAL_TRIAL ] ... Description Indolent lymphoma is a slow growing but incurable lymphoma which includes follicular lymphoma and marginal zone lymphoma. Follicular lymphoma and marginal zone lymphoma are ...
Known for star star star star star_half
Refractory Indolent | Rituximab Lenalidomide | Follicular Lymphoma | Marginal Zone

A Pilot Phase Ii Study Of New Direct-Acting Antiviral Agent, Harvoni®...

[ CLINICAL_TRIAL ] ... B-cell lymphoma (MZ), lymphoplasmacytic lymphoma (LPL, also known as Waldenström's macroglobulinemia), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL). The sustained ...
Known for star star star star star_border
Hcv Indolent | Antiviral Agent | Lymphoma Nhl | Infection Daas

A Multicenter, Open-Label, Noncomparative Study Of Enzastaurin In Patients With...

[ CLINICAL_TRIAL ] ... lymphoma, Indolent B-cell lymphoma, and Aggressive B-cell lymphoma. Each tumor type will include several tumor subtypes:T-cell lymphoma: Peripheral and Cutaneous T-cell lymphoma (PTCL, ...
Known for star star star star star_border
Lymphoma Tumor | Investigational Drug | Prior History

A Global Multicenter Phase 1/2 Trial Of Eo2463, A Novel Microbial-Derived Peptide...

[ CLINICAL_TRIAL ] ... Lymphoma
Known for star star star star star_border
Hodgkins Lymphoma | Multicenter Phase | Derived Peptide | Therapeutic Vaccine

A Phase 2, Open-Label Study Evaluating The Efficacy, Safety, Tolerability, And...

[ CLINICAL_TRIAL ] ... cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas (iNHL; including lymphoplasmacytoid lymphoma/ Waldenström ...
Known for star star star star star_border
Hematologic Malignancies | Relapsed Refractory | Evaluate Entospletinib | Primary Objective